Emerging drugs for small cell lung cancer - An update

Expert Opinion on Emerging Drugs

Volumn 17, Issue 1, 2012, Pages 31-36

  Metro, Giulio ^a   Duranti, Simona ^a   Fischer, Matthias Joachim ^a   Cappuzzo, Federico ^b   Crinò, Lucio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b Livorno Hospital   (Italy)

Author keywords

amrubicin; apoptosis; Bcl 2 inhibitors; bevacizumab; hedgehog pathway; obatoclax; picoplatin; small cell lung cancer; TRAIL

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CYCLOPAMINE; ETOPOSIDE; IRINOTECAN; ISOSORBIDE; NAVITOCLAX; OBATOCLAX; PICOPLATIN; SONIC HEDGEHOG PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APPETITE DISORDER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER TISSUE; CELL DIFFERENTIATION; CELL GROWTH; CHEMORADIOTHERAPY; COUGHING; DRUG SENSITIVITY; DYSPNEA; EUPHORIA; HUMAN; JAPAN; LUNG SMALL CELL CANCER; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HEDGEHOG PROTEINS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SMALL CELL LUNG CARCINOMA;

EID: 84858986573     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.656588     Document Type: Short Survey

References (33)

1. Metro G, Cappuzzo F. Emerging drugs for small-cell lung cancer. Expert Opin Emerg Drugs 2009;14:591-606
2. Rossi A, Di Maio M, Chiodini P, et al. COCIS individual patient data (IPD) meta-analysis: carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2011;29(Suppl):7022 Individual patient meta-analysis showing that carboplatin - etoposide is equivalent to cisplatin - etoposide in the first-line treatment of ES-SCLC.
3. Goldstein SD, Yang SC. Role of surgery in small cell lung cancer. Surg Oncol Clin N Am 2011;20:769-77
4. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7 Study showing that second-line chemotherapy improves survival in relapsed SCLC. (Pubitemid 46623178)
5. Ciuleanu T, Samarzja M, Demidchil Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy [abstract]. J Clin Oncol 2010;28(Suppl):7002
6. Tang CH, Parham C, Shocron E, et al. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol 2011;67:1389-400
7. Kimura T, Kudoh S, Hirata K. Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride. Clin Med Insight Oncol 2011;5:23-34
8. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-603
9. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287-93
10. Jotte R, Von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan (topo) as second-line treatment for small cell lung cancer (SCLC) [abstract]. J Clin Oncol 2011;29(Suppl):7000
11. O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer 2011;47:2322-30
12. Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:119-28
13. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-11
14. Spigel DR, Greco FA, Zubkus JD, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009;4:1555-6015.
15. Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study. J Clin Oncol 2011;29:4436-41
16. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-8
17. Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-2218.
18. Bevacizumab in Extensive Small Cell Lung Cancer. Available from: http:// clinicaltrials.gov/ct2/results? term=NCT00930891 [Last accessed 1 November 2011]
19. Dean EJ, Cummings J, Roulston A, et al. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia 2011;13:339-47
20. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008;8:121-32 (Pubitemid 351161322)
21. Langer CJ, Albert I, Kovacs P, et al. A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC) [abstract]. J Clin Oncol 2011;29:7001
22. Pore MM, Hiltermann TJ, Kruyt FA. Targeting apoptosis pathways in lung cancer. Cancer Lett 2010;In press
23. Hubaux R, Vandermeers F, Crisanti MC, et al. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer 2010;46:1724-34
24. Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011;32:1450-8
25. Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501
26. Edwards DK, Allen KE, Arora S, et al. Mechanism for Gli1-induced resistance to combination cisplatin and etoposide in small-cell lung cancer [abstract]. Undergraduate Research Poster Symposium; 2011
27. Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ ct2/results?term=NCT00887159 [Last accessed 1 November 2011]
28. A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ ct2/results?term=NCT00927875 [Last accessed 1 November 2011]
29. Olejniczak ET, Van Sant C, Anderson MG, et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 2007;5:331-9 (Pubitemid 46706995)
30. Tahir SK, Wass J, Joseph MK, et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 2010;9:545-57
31. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363:775-81 (Pubitemid 38315167)
32. Ranade AR, Cherba D, Sridhar S, et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 2010;5:1273-8
33. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67 Study leading to the approval of topotecan for relapsed SCLC. (Pubitemid 29075255)